7.3 Amyotrophic Lateral Sclerosis & Neuromuscular Junction Disorders

Amyotrophic Lateral Sclerosis & Neuromuscular Junction Disorders

Pathophysiology of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease, is a devastating, rapidly progressive, and universally fatal neurodegenerative disease. The fundamental pathophysiology of ALS is the simultaneous, inexorable degeneration of both upper & lower motor neuron degeneration. Upper motor neurons (UMNs), originating in the motor cortex of the brain and descending through the corticospinal and corticobulbar tracts, and lower motor neurons (LMNs), located in the anterior horn of the spinal cord and the brainstem motor nuclei, undergo apoptosis. The destruction of UMNs leads to spasticity, hyperreflexia, and positive pathological reflexes such as the Babinski sign. Conversely, the degeneration of LMNs results in profound muscle flaccidity, severe atrophy, hyporeflexia, and widespread fasciculations (muscle twitches). The exact etiology of this motor neuron death remains largely elusive, although theories heavily implicate glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, and neuroinflammation. Approximately 5-10% of cases are familial, often associated with mutations in the C9orf72, SOD1, or TARDBP genes. Strikingly, ALS selectively attacks the motor system, generally sparing sensory function, cognitive abilities, and the autonomic nervous system, including bowel and bladder control, meaning the patient remains fully cognitively intact while becoming entirely physically locked in.

Clinical Manifestations and Progression of ALS

The clinical presentation of ALS varies depending on whether the onset is limb-onset or bulbar-onset. Limb-onset ALS typically presents with asymmetric, distal muscle weakness, such as difficulty grasping objects, foot drop, or frequent tripping. Bulbar-onset ALS, which carries a significantly worse prognosis due to early respiratory and swallowing compromise, presents with dysarthria (slurred speech) and dysphagia (difficulty swallowing). As the disease progresses, patients experience a relentlessly spreading weakness that eventually encompasses the muscles of respiration, specifically the diaphragm and intercostal muscles. The convergence of UMN and LMN signs in the same anatomical region is the clinical hallmark required for diagnosis. Electromyography (EMG) reveals widespread acute and chronic denervation and reinnervation changes. The average survival from the time of symptom onset is brutally short, typically 2 to 5 years, with respiratory failure acting as the primary cause of mortality.

Medical and Pharmacological Management of ALS

While there is no cure for ALS, specific pharmacological agents can marginally slow disease progression. Riluzole is a glutamate antagonist that has been shown to prolong survival by approximately two to three months or delay the need for a tracheostomy. Nurses must monitor liver function tests (LFTs) closely when administering riluzole, as hepatotoxicity is a primary adverse effect. Edaravone, a free radical scavenger, may slow the decline of physical function in select patients, particularly those in the early stages of the disease. It is administered via intravenous infusion. The vast majority of pharmacological management in ALS is entirely palliative, focusing intensely on symptom control. This includes using anticholinergics (e.g., glycopyrrolate, amitriptyline) to manage severe sialorrhea (drooling) caused by the inability to swallow saliva, and administering muscle relaxants (e.g., baclofen) to treat painful spasticity and cramping.

Advanced Care: Respiratory and Nutritional Interventions

The most critical nursing interventions in ALS involve anticipating and aggressively managing respiratory and nutritional failure. As diaphragmatic weakness progresses, patients will inevitably require non-invasive ventilation (NIV), such as BiPAP, initially during sleep to manage sleep-disordered breathing and hypoventilation, and eventually continuously. The timely initiation of NIV has been definitively shown to improve both survival and quality of life. Secretion clearance is managed with a mechanical in-exsufflator (cough assist device) to prevent pneumonia. Concurrently, severe dysphagia poses a massive risk for malnutrition, dehydration, and aspiration pneumonia. To ensure adequate caloric intake and medication administration safely, proactive PEG placement (Percutaneous Endoscopic Gastrostomy) is strongly recommended before the patient's forced vital capacity (FVC) drops below 50%, as the procedure becomes exceedingly high-risk with severe respiratory compromise. CNRNs must initiate incredibly difficult, compassionate conversations regarding advanced directives, mechanical ventilation, and hospice care early in the disease trajectory.

Neuromuscular Junction Disorders: Myasthenia Gravis

In contrast to the motor neuron death in ALS, Myasthenia Gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction. Pathophysiologically, autoantibodies specifically target and destroy acetylcholine receptors (AChRs) on the postsynaptic muscle membrane, severely impairing neuromuscular transmission and leading to fluctuating, fatigable muscle weakness. The weakness typically worsens with exertion and improves with rest. Ocular symptoms (ptosis and diplopia) are incredibly common, often progressing to bulbar symptoms (dysphagia, dysarthria) and generalized limb weakness. The Tensilon (edrophonium) test, though largely replaced by serological testing and EMG, historically demonstrated rapid, transient improvement in strength by inhibiting acetylcholinesterase. Long-term management relies on acetylcholinesterase inhibitors like pyridostigmine, which increase acetylcholine availability at the junction. Immunosuppressants (corticosteroids, azathioprine) and thymectomy are also utilized. A critical, life-saving nursing assessment involves distinguishing between a Myasthenic Crisis (a severe exacerbation of the disease leading to respiratory failure, requiring IVIG or plasmapheresis) and a Cholinergic Crisis (an overdose of anticholinesterase medication causing profound weakness and extreme parasympathetic overactivity, such as severe bradycardia, excessive salivation, miosis, and fasciculations). Differentiating these two emergencies is a classic, vital CNRN competency.